TLR9 and endogenous adjuvants of the whole blood-stage malaria vaccine

References

• Pierce SK, Miller LH. World Malaria Day 2009: what malaria knows about the immune system that immunologists still do not. J. Immunol.182(9), 5171–5177 (2009).
   PubMed Web of Science ®Google Scholar
• Good MF. The hope but challenge for developing a vaccine that might control malaria. Eur. J. Immunol.39(4), 939–943 (2009).
   PubMed Web of Science ®Google Scholar
• Doolan DL, Dobano C, Baird JK. Acquired immunity to malaria. Clin. Microbiol. Rev.22(1), 13–36 (2009).
   PubMed Web of Science ®Google Scholar
• Vanderberg JP. Reflections on early malaria vaccine studies, the first successful human malaria vaccination, and beyond. Vaccine27(1), 2–9 (2009).
   PubMed Web of Science ®Google Scholar
• Girard MP, Reed ZH, Friede M, Kieny MP. A review of human vaccine research and development: malaria. Vaccine25(9), 1567–1580 (2007).
   PubMed Web of Science ®Google Scholar
• Plebanski M, Locke E, Kazura JW, Coppel RL. Malaria vaccines: into a mirror, darkly? Trends Parasitol.24(12), 532–536 (2008).
   PubMed Web of Science ®Google Scholar
• Holder AA. Malaria vaccines: where next? PLoS Pathog.5(10), e1000638 (2009).
   Google Scholar
• Haque A, Good MF. Malaria vaccine research: lessons from 2008/9. Future Microbiol.4, 649–654 (2009).
   PubMed Web of Science ®Google Scholar
• Cohen J, Nussenzweig V, Nussenzweig R, Vekemans J, Leach A. From the circumsporozoite protein to the RTS,S/AS candidate vaccine. Hum. Vaccin.6(1), 90–96 (2009).
   Google Scholar
• Coppel RL. Vaccinating with the genome: a Sisyphean task? Trends Parasitol.25(5), 205–212 (2009).
   PubMed Web of Science ®Google Scholar
• Okech B, Mujuzi G, Ogwal A, Shirai H, Horii T, Egwang TG. High titers of IgG antibodies against Plasmodium falciparum serine repeat antigen 5 (SERA5) are associated with protection against severe malaria in Ugandan children. Am. J. Trop. Med. Hyg.74(2), 191–197 (2006).
   PubMed Web of Science ®Google Scholar
• McCoubrie JE, Miller SK, Sargeant T et al. Evidence for a common role for the serine-type Plasmodium falciparum serine repeat antigen proteases: implications for vaccine and drug design. Infect. Immun.75(12), 5565–5574 (2007).
   PubMed Web of Science ®Google Scholar
• Coler RN, Carter D, Friede M, Reed SG. Adjuvants for malaria vaccines. Parasite Immunol.31(9), 520–528 (2009).
   PubMed Web of Science ®Google Scholar
• Douradinha B, Mota MM, Luty AJ, Sauerwein RW. Cross-species immunity in malaria vaccine development: two, three, or even four for the price of one? Infect. Immun.76(3), 873–878 (2008).
   PubMed Web of Science ®Google Scholar
• Ishii KJ, Koyama S, Nakagawa A, Coban C, Akira S. Host innate immune receptors and beyond: making sense of microbial infections. Cell Host Microbe3(6), 352–363 (2008).
   PubMed Web of Science ®Google Scholar
• Marrack P, McKee AS, Munks MW. Towards an understanding of the adjuvant action of aluminium. Nat. Rev. Immunol.9(4), 287–293 (2009).
   PubMed Web of Science ®Google Scholar
• Harandi AM, Medaglini D, Shattock RJ. Vaccine adjuvants: a priority for vaccine research. Vaccine28(12), 2363–2366 (2010).
   PubMed Web of Science ®Google Scholar
• Ballou WR. The development of the RTS,S malaria vaccine candidate: challenges and lessons. Parasite Immunol.31(9), 492–500 (2009).
   PubMed Web of Science ®Google Scholar
• Ishii KJ, Akira S. Toll or toll-free adjuvant path toward the optimal vaccine development. J. Clin. Immunol.27(4), 363–371 (2007).
   PubMed Web of Science ®Google Scholar
• Pulendran B, Ahmed R. Translating innate immunity into immunological memory: implications for vaccine development. Cell124(4), 849–863 (2006).
   PubMed Web of Science ®Google Scholar
• Palm NW, Medzhitov R. Pattern recognition receptors and control of adaptive immunity. Immunol. Rev.227(1), 221–233 (2009).
   PubMed Web of Science ®Google Scholar
• Koyama S, Ishii KJ, Kumar H et al. Differential role of TLR- and RLR-signaling in the immune responses to influenza A virus infection and vaccination. J. Immunol.179(7), 4711–4720 (2007).
   PubMed Web of Science ®Google Scholar
• Ishii KJ, Kawagoe T, Koyama S et al. TANK-binding kinase-1 delineates innate and adaptive immune responses to DNA vaccines. Nature451(7179), 725–729 (2008).
   PubMed Web of Science ®Google Scholar
• Coban C, Koyama S, Takeshita F, Akira S, Ishii KJ. Molecular and cellular mechanisms of DNA vaccines. Hum. Vaccin.4(6), 453–456 (2008).
   PubMed Web of Science ®Google Scholar
• Ishikawa H, Ma Z, Barber GN. STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity. Nature461(7265), 788–792 (2009).
   PubMed Web of Science ®Google Scholar
• Vaughan AM, Wang R, Kappe SH. Genetically engineered, attenuated whole-cell vaccine approaches for malaria. Hum. Vaccin.6(1), 107–113 (2010).
   PubMed Web of Science ®Google Scholar
• Hoffman SL, Billingsley PF, James E et al. Development of a metabolically active, non-replicating sporozoite vaccine to prevent Plasmodium falciparum malaria. Hum. Vaccin.6(1), 97–106 (2010).
   PubMed Web of Science ®Google Scholar
• Hoffman SL, Goh LM, Luke TC et al. Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites. J. Infect. Dis.185(8), 1155–1164 (2002).
   PubMed Web of Science ®Google Scholar
• Doolan DL, Martinez-Alier N. Immune response to pre-erythrocytic stages of malaria parasites. Curr. Mol. Med.6(2), 169–185 (2006).
   PubMed Web of Science ®Google Scholar
• Mueller AK, Labaied M, Kappe SH, Matuschewski K. Genetically modified Plasmodium parasites as a protective experimental malaria vaccine. Nature433(7022), 164–167 (2005).
   PubMed Web of Science ®Google Scholar
• Purcell LA, Wong KA, Yanow SK, Lee M, Spithill TW, Rodriguez A. Chemically attenuated Plasmodium sporozoites induce specific immune responses, sterile immunity and cross-protection against heterologous challenge. Vaccine26(38), 4880–4884 (2008).
   PubMed Web of Science ®Google Scholar
• Belnoue E, Costa FTM, Frankenberg T et al. Protective T cell immunity against malaria liver stage after vaccination with live sporozoites under chloroquine treatment. J. Immunol.172(4), 2487–2495 (2004).
   PubMed Web of Science ®Google Scholar
• Roestenberg M, McCall M, Hopman J et al. Protection against a malaria challenge by sporozoite inoculation. N. Engl. J. Med.361(5), 468–477 (2009).
   PubMed Web of Science ®Google Scholar
• Belnoue E, Voza T, Costa FT et al. Vaccination with live Plasmodium yoelii blood stage parasites under chloroquine cover induces cross-stage immunity against malaria liver stage. J. Immunol.181(12), 8552–8558 (2008).
   PubMed Web of Science ®Google Scholar
• Renia L, Gruner AC, Mauduit M, Snounou G. Vaccination against malaria with live parasites. Expert Rev. Vaccines5(4), 473–481 (2006).
   PubMed Web of Science ®Google Scholar
• Freund J, Sommer HE, Walter AW. Immunization against malaria: vaccination of ducks with killed parasites incorporated with adjuvants. Science102(2643), 200–202 (1945).
   PubMed Web of Science ®Google Scholar
• Freund J, Thomson KJ, Sommer HE, Walter AW, Schenkein EL. Immunization of rhesus monkeys against malarial infection (P. knowlesi) with killed parasites and adjuvants. Science102(2643), 202–204 (1945).
   PubMed Web of Science ®Google Scholar
• McCarthy JS, Good MF. Whole parasite blood stage malaria vaccines: a convergence of evidence. Hum. Vaccin.6(1), 114–123 (2010).
   PubMed Web of Science ®Google Scholar
• Su Z, Tam MF, Jankovic D, Stevenson MM. Vaccination with novel immunostimulatory adjuvants against blood-stage malaria in mice. Infect. Immun.71(9), 5178–5187 (2003).
   PubMed Web of Science ®Google Scholar
• Ting LM, Gissot M, Coppi A, Sinnis P, Kim K. Attenuated Plasmodium yoelii lacking purine nucleoside phosphorylase confer protective immunity. Nat. Med.14(9), 954–958 (2008).
   PubMed Web of Science ®Google Scholar
• Aly AS, Downie MJ, Mamoun CB, Kappe SH. Subpatent infection with nucleoside transporter 1-deficient Plasmodium blood stage parasites confers sterile protection against lethal malaria in mice. Cell. Microbiol. DOI: 10.1111/j.1462-5822. 2010.01441.x (2010) (Epub ahead of print).
   PubMedGoogle Scholar
• Sauerwein RW. Malaria transmission-blocking vaccines: the bonus of effective malaria control. Microbes Infect.9(6), 792–795 (2007).
   PubMed Web of Science ®Google Scholar
• Pombo DJ, Lawrence G, Hirunpetcharat C et al. Immunity to malaria after administration of ultra-low doses of red cells infected with Plasmodium falciparum. Lancet360(9333), 610–617 (2002).
   PubMed Web of Science ®Google Scholar
• Pichyangkul S, Yongvanitchit K, Kum-arb U et al. Malaria blood stage parasites activate human plasmacytoid dendritic cells and murine dendritic cells through a Toll-like receptor 9-dependent pathway. J. Immunol.172(8), 4926–4933 (2004).
   PubMed Web of Science ®Google Scholar
• Krishnegowda G, Hajjar AM, Zhu J et al. Induction of proinflammatory responses in macrophages by the glycosylphosphatidylinositols of Plasmodium falciparum: cell signaling receptors, glycosylphosphatidylinositol (GPI) structural requirement, and regulation of GPI activity. J. Biol. Chem.280(9), 8606–8616 (2005).
   PubMed Web of Science ®Google Scholar
• Coban C, Ishii KJ, Kawai T et al. Toll-like receptor 9 mediates innate immune activation by the malaria pigment hemozoin. J. Exp. Med.201(1), 19–25 (2005).
   PubMed Web of Science ®Google Scholar
• Parroche P, Lauw FN, Goutagny N et al. Malaria hemozoin is immunologically inert but radically enhances innate responses by presenting malaria DNA to Toll-like receptor 9. Proc. Natl Acad. Sci. USA104(6), 1919–1924 (2007).
   PubMed Web of Science ®Google Scholar
• Seixas E, Moura Nunes JF, Matos I, Coutinho A. The interaction between DC and Plasmodium berghei/chabaudi-infected erythrocytes in mice involves direct cell-to-cell contact, internalization and TLR. Eur. J. Immunol.39(7), 1850–1863 (2009).
   PubMed Web of Science ®Google Scholar
• Coban C, Igari Y, Yagi M et al. Immunogenicity of whole-parasite vaccines against Plasmodium falciparum involves malarial hemozoin and host TLR9. Cell Host Microbe7(1), 50–61 (2010).
   PubMed Web of Science ®Google Scholar
• Schofield L, Hewitt MC, Evans K, Siomos MA, Seeberger PH. Synthetic GPI as a candidate anti-toxic vaccine in a model of malaria. Nature418(6899), 785–789 (2002).
   PubMed Web of Science ®Google Scholar
• Gilson PR, Nebl T, Vukcevic D et al. Identification and stoichiometry of glycosylphosphatidylinositol-anchored membrane proteins of the human malaria parasite Plasmodium falciparum. Mol. Cell Proteomics5(7), 1286–1299 (2006).
   PubMed Web of Science ®Google Scholar
• Culleton R, Ndounga M, Zeyrek FY et al. Evidence for the transmission of Plasmodium vivax in the Republic of the Congo, West Central Africa. J. Infect. Dis.200(9), 1465–1469 (2009).
   PubMed Web of Science ®Google Scholar
• Coban C, Yagi M, Ohata K et al. The malarial metabolite hemozoin and its potential use as a vaccine adjuvant. Allergol. Int.59(2), 115–124 (2010).
   PubMedGoogle Scholar
• Coban C, Ishii KJ, Horii T, Akira S. Manipulation of host innate immune responses by the malaria parasite. Trends Microbiol.15(6), 271–278 (2007).
   PubMed Web of Science ®Google Scholar
• Adachi K, Tsutsui H, Kashiwamura S et al.Plasmodium berghei infection in mice induces liver injury by an IL-12- and Toll-like receptor/myeloid differentiation factor 88-dependent mechanism. J. Immunol.167(10), 5928–5934 (2001).
   PubMed Web of Science ®Google Scholar
• Coban C, Ishii KJ, Uematsu S et al. Pathological role of Toll-like receptor signaling in cerebral malaria. Int. Immunol.19(1), 67–79 (2007).
   PubMed Web of Science ®Google Scholar
• Griffith JW, O’Connor C, Bernard K, Town T, Goldstein DR, Bucala R. Toll-like receptor modulation of murine cerebral malaria is dependent on the genetic background of the host. J. Infect. Dis.196(10), 1553–1564 (2007).
   PubMed Web of Science ®Google Scholar
• Togbe D, Schofield L, Grau GE et al. Murine cerebral malaria development is independent of Toll-like receptor signaling. Am. J. Pathol.170(5), 1640–1648 (2007).
   PubMed Web of Science ®Google Scholar
• Lepenies B, Cramer JP, Burchard GD, Wagner H, Kirschning CJ, Jacobs T. Induction of experimental cerebral malaria is independent of TLR2/4/9. Med. Microbiol. Immunol.197(1), 39–44 (2008).
   PubMed Web of Science ®Google Scholar
• Ivanov II, Atarashi K, Manel N et al. Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell139(3), 485–498 (2009).
   PubMed Web of Science ®Google Scholar
• Voisine C, Mastelic B, Sponaas AM, Langhorne J. Classical CD11c+ dendritic cells, not plasmacytoid dendritic cells, induce T cell responses to Plasmodium chabaudi malaria. Int. J. Parasitol.40(6), 711–719 (2009).
   PubMed Web of Science ®Google Scholar
• Franklin BS, Rodrigues SO, Antonelli LR et al. MyD88-dependent activation of dendritic cells and CD4+ T lymphocytes mediates symptoms, but is not required for the immunological control of parasites during rodent malaria. Microbes Infect.9(7), 881–890 (2007).
   PubMed Web of Science ®Google Scholar
• Franklin BS, Parroche P, Ataide MA et al. Malaria primes the innate immune response due to interferon-g induced enhancement of Toll-like receptor expression and function. Proc. Natl Acad. Sci. USA106(14), 5789–5794 (2009).
   PubMed Web of Science ®Google Scholar
• Cramer JP, Lepenies B, Kamena F et al. MyD88/IL-18-dependent pathways rather than TLRs control early parasitaemia in non-lethal Plasmodium yoelii infection. Microbes Infect.10(12–13), 1259–1265 (2008).
   PubMed Web of Science ®Google Scholar
• Hisaeda H, Tetsutani K, Imai T et al. Malaria parasites require TLR9 signaling for immune evasion by activating regulatory T cells. J. Immunol.180(4), 2496–2503 (2008).
   PubMed Web of Science ®Google Scholar
• Scholzen A, Minigo G, Plebanski M. Heroes or villains? T regulatory cells in malaria infection. Trends Parasitol.26(1), 16–25 (2010).
   PubMed Web of Science ®Google Scholar
• Beeson JG, Osier FH, Engwerda CR. Recent insights into humoral and cellular immune responses against malaria. Trends Parasitol.24(12), 578–584 (2008).
   PubMed Web of Science ®Google Scholar
• Struik SS, Riley EM. Does malaria suffer from lack of memory? Immunol. Rev.201, 268–290 (2004).
   PubMed Web of Science ®Google Scholar
• Wipasa J, Suphavilai C, Okell LC et al. Long-lived antibody and B cell memory responses to the human malaria parasites, Plasmodium falciparum and Plasmodium vivax. PLoS Pathog.6(2), e1000770 (2010).
   Google Scholar
• Pierce SK. Understanding B cell activation: from single molecule tracking, through Tolls, to stalking memory in malaria. Immunol. Res.43(1–3), 85–97 (2009).
   PubMed Web of Science ®Google Scholar
• Crompton PD, Mircetic M, Weiss G et al. The TLR9 ligand CpG promotes the acquisition of Plasmodium falciparum-specific memory B cells in malaria-naive individuals. J. Immunol.182(5), 3318–3326 (2009).
   PubMed Web of Science ®Google Scholar
• Traore B, Kone Y, Doumbo S et al. The TLR9 agonist CpG fails to enhance the acquisition of Plasmodium falciparum -specific memory B cells in semi-immune adults in Mali. Vaccine27(52), 7299–7303 (2009).
   PubMed Web of Science ®Google Scholar
• Loharungsikul S, Troye-Blomberg M, Amoudruz P et al. Expression of Toll-like receptors on antigen-presenting cells in patients with falciparum malaria. Acta Trop.105(1), 10–15 (2008).
   PubMed Web of Science ®Google Scholar
• Jangpatarapongsa K, Chootong P, Sattabongkot J et al.Plasmodium vivax parasites alter the balance of myeloid and plasmacytoid dendritic cells and the induction of regulatory T cells. Eur. J. Immunol.38(10), 2697–2705 (2008).
   PubMed Web of Science ®Google Scholar
• McCall MB, Netea MG, Hermsen CC et al.Plasmodium falciparum infection causes proinflammatory priming of human TLR responses. J. Immunol.179(1), 162–171 (2007).
   PubMed Web of Science ®Google Scholar
• Mockenhaupt FP, Hamann L, von Gaertner C et al. Common polymorphisms of Toll-like receptors 4 and 9 are associated with the clinical manifestation of malaria during pregnancy. J. Infect. Dis.194(2), 184–188 (2006).
   PubMed Web of Science ®Google Scholar
• Greene JA, Moormann AM, Vulule J, Bockarie MJ, Zimmerman PA, Kazura JW. Toll-like receptor polymorphisms in malaria-endemic populations. Malar. J.8, 50 (2009).
   PubMedGoogle Scholar
• Campino S, Forton J, Auburn S et al. TLR9 polymorphisms in African populations: no association with severe malaria, but evidence of cis-variants acting on gene expression. Malar. J.8, 44 (2009).
   PubMedGoogle Scholar
• Leoratti FM, Farias L, Alves FP et al. Variants in the Toll-like receptor signaling pathway and clinical outcomes of malaria. J. Infect. Dis.198(5), 772–780 (2008).
   PubMed Web of Science ®Google Scholar
• Torcia MG, Santarlasci V, Cosmi L et al. Functional deficit of T regulatory cells in Fulani, an ethnic group with low susceptibility to Plasmodium falciparum malaria. Proc. Natl Acad. Sci. USA105(2), 646–651 (2008).
   PubMed Web of Science ®Google Scholar
• Yoshida S, Araki H, Yokomine T. Baculovirus-based nasal drop vaccine confers complete protection against malaria by natural boosting of vaccine-induced antibodies in mice. Infect. Immun.78(2), 595–602 (2010).
   PubMed Web of Science ®Google Scholar
• Cadman ET, Abdallah AY, Voisine C et al. Alterations of splenic architecture in malaria are induced independently of Toll-like receptors 2, 4, and 9 or MyD88 and may affect antibody affinity. Infect. Immun.76(9), 3924–3931 (2008).
   PubMed Web of Science ®Google Scholar